Management of multiple myeloma during COVID-19 pandemic
Y S Jethava1, Rafael Fonseca2, Ola Landgren3
1Division of Hematology and Cellular Therapy, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, 5970 JPP, Iowa City, IA 52242, United States.
Insights
A novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), caused a pneumonia outbreak in Wuhan, China, in late 2019. The World Health Organization declared COVID-19 a pandemic in March 2020.
Area of Science:
- * Infectious Diseases
- * Virology
- * Public Health
Background:
- * A novel coronavirus emerged in Wuhan, China, in late 2019, causing pneumonia.
- * The outbreak rapidly escalated, leading to global concern.
Purpose of the Study:
- * To identify the causative agent of the pneumonia outbreak.
- * To track the emergence and spread of the novel coronavirus disease.
Main Methods:
- * Identification of a novel coronavirus from patient samples.
- * Epidemiological investigation of the pneumonia cases.
Main Results:
- * The virus responsible was identified as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).
- * The disease caused by SARS-CoV-2 was officially named COVID-19 by the World Health Organization in February 2020.
Conclusions:
- * The emergence of SARS-CoV-2 led to a significant public health crisis.
- * The rapid global spread necessitated the declaration of a pandemic by March 2020.
Abstract:
At the end of 2019, a novel coronavirus was identified as the cause of pneumonia cases in Wuhan, a city in the Hubei Province of China. On January 30, 2020, the World Health Organization (WHO) declared the COVID-19 outbreak a public health emergency of international concern and, in March 2020, began to characterize it as a pandemic. The virus that causes COVID-19 is designated severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) In February 2020, the World Health Organization designated the disease COVID-19, which stands for coronavirus disease 2019.
More Related Videos
09:41An Organotypic High Throughput System for Characterization of Drug Sensitivity of Primary Multiple Myeloma Cells
Published on: July 15, 2015
10:04Establishment of a Human Multiple Myeloma Xenograft Model in the Chicken to Study Tumor Growth, Invasion and Angiogenesis
Published on: May 1, 2015
Related Concept Videos
01:14Myocarditis III: Medical Management
01:22Myocarditis IV: Nursing Management
02:56Treatment Resistant Cancers
01:20Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
01:17Pericarditis III: Medical Management
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...